Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: Lack of dependence upon opioid receptor activation

AAPS Journal

Volumn 12, Issue 2, 2010, Pages 147-157

  Rahn, Elizabeth J ^a   Zvonok, Alexander M ^b   Makriyannis, Alexandros ^b   Hohmann, Andrea G ^a  

^a University of Georgia   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Antinociception; Cannabinoid; CB2; Endogenous opioid; Naloxone; Pain

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; MORPHINE; NALOXONE; OPIATE RECEPTOR; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CHIRALITY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; LOW DRUG DOSE; MALE; MECHANICAL STIMULATION; NONHUMAN; PAIN RECEPTOR; PAIN THRESHOLD; PAW EDEMA; PROTEIN FUNCTION; RAT; SEIZURE; STIMULUS RESPONSE; THERMAL STIMULATION;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; CANNABINOIDS; HOT TEMPERATURE; ISOMERISM; MALE; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PAIN THRESHOLD; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950634809     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9170-8     Document Type: Article

References (36)

1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86(8):1946-1947
2. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids. 2002;121(1-2):173-190
3. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153(2):319-334
4. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713-737
5. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96(10):5780-5785 (Pubitemid 29234695)
6. Onaivi ES. An endocannabinoid hypothesis of drug reward and drug addiction. Ann N Y Acad Sci. 2008;1139:412-421
7. Wiley JL, Martin BR. Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol. 2003;471(3):185-193
8. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329-332
9. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci. 2006;1074:514-536 (Pubitemid 44532857)
10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-65 (Pubitemid 23305569)
11. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000;396(2-3):141-149 (Pubitemid 30265571)
12. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, et al. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci. 2006;23(6):1530-1538
13. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience. 2005;135(1):235-245 (Pubitemid 41219752)
14. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci. 2003;17(12):2750-2754 (Pubitemid 36819300)
15. Jhaveri MD, Elmes SJ, Richardson D, Barrett DA, Kendall DA, Mason R, et al. Evidence for a novel functional role of cannabinoid CB receptors in the thalamus of neuropathic rats. Eur J Neurosci. 2008;27(7):1722-1730 (Pubitemid 351473595)
16. Malan Jr TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 2001;93(3):239-245 (Pubitemid 32763181)
17. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, et al. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999;96(25):14228-14233 (Pubitemid 30000633)
18. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, et al. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol. 2006;149(2):145-154 (Pubitemid 44360095)
19. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA, et al. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol. 2007;151(7):1061-1070 (Pubitemid 47195523)
20. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A. 2005;102(8):3093-3098 (Pubitemid 40299921)
21. Yao BB, Hsieh G, Daza AV, Fan Y, Grayson GK, Garrison TR, et al. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2, 2, 3, 3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4, 5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging. J Pharmacol Exp Ther. 2009;328(1):141-151
22. Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV, et al. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol. 2008;153(2):390-401.
23. Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, et al. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist,GW405833. Eur J Pharmacol. 2005;528(1-3):65-72.
24. Thakur GA, Nikas SP, Li C, Makriyannis A. Structural requirements for cannabinoid receptor probes. Handb Exp Pharmacol. 2005;168:209-246
25. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983;16(2):109-110 (Pubitemid 13058546)
26. Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 2003;119:747-757 (Pubitemid 36694801)
27. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stressinduced analgesia. Nature. 2005;435(7045):1108-1112
28. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32(1):77-88.
29. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, et al. CB2 cannabinoid receptor mediation of antinociception. Pain. 2006;122(1-2):36-42.
30. Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther. 2008;327(2):584-591
31. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol. 2004;92(6):3562-3574 (Pubitemid 39506332)
32. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A. 2003;100:10529-10533 (Pubitemid 37071912)
33. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol. 2007;150(2):153-163 (Pubitemid 46160605)
34. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience. 2008;152(3):753-760
35. Tall JM. Housing supplementation decreases the magnitude of inflammation-induced nociception in rats. Behav Brain Res. 2009;197(1):230-233
36. Naguib M, Diaz P, Xu JJ, Astruc-Diaz F, Craig S, Vivas-Mejia P, et al. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol. 2008;155(7):1104-1116